Compare iShares Core High Dividend ETF (HDV) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Novartis AG — how do they compare? iShares Core High Dividend ETF trades at $28.78 (market cap $14.72B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 18.6× iShares Core High Dividend ETF's market cap, and Novartis AG pays a 3.31% dividend while iShares Core High Dividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Novartis AG for 82 Days on average.
| HDV | NVS | |
|---|---|---|
Market Cap | $14.72B | $274.00B |
Volume | 2,297,177 | 1,852,137 |
52-Week High | $29.93 | $168.62 |
52-Week Low | $23.64 | $121.80 |
Typical Hold Time | 117 Days | 82 Days |
Sector | — | Health |
Enterprise Value | — | $315.32B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.28, down 0.28% with neutral technical signals. The ETF recently underwent significant sector rebalancing, reducing healthcare exposure by nearly half while increasing energy, staples, and utilities. Technical indicators show mixed signals with bearish moving averages but neutral oscillators. Recent dividend payments of $0.06-$0.10 per share demonstrate consistent income generation, though the fund's 3% yield may not fully compensate for increased concentration risks.
The outlook remains cautious as HDV's sector concentration (62% in three sectors) creates heightened risk exposure. While the dividend yield provides income stability, the fund's recent underperformance relative to peers and reduced diversification warrant careful monitoring. Investors should weigh the trade-off between current income and long-term growth potential given the significant portfolio restructuring.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
